Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement
About this episode
Patrick Baeuerle and Jeffrey Miller discuss T cell and immune cell engagement and its advantages over other therapies.
T cell and immune cell engagement is gaining traction, but what makes it different from other therapies? Patrick Baeuerle, Ph.D., chief scientific advisor at Cullinan Therapeutics, and Jeffrey Miller, M.D., deputy director of Masonic Cancer Center, join The Chain to discuss the advantages, similarities, and differences of T cell and immune cell engagers, and how they compare to other modalities such as CAR T cells. Hosted by Laszlo Radvanyi, Ph.D., their conversation covers engineering recogn...
Topics covered
- T cell engagement
- immune cell engagement
- therapies
- CAR T cells
- cancer treatment
More episodes of The Chain: Protein Engineering Podcast
- Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating
- Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies?
- Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research
- Episode: 80 - Vibha Jawa Discusses the Impact of Biologic Molecules and the Future of Immunogenicity
- Episode: 79 - Conversation with Bahija Jallal on the Biggest Anticipated Transformations and Breakthroughs
- Episode: 78 - Shamit Shrivastava on an Interdisciplinary Approach to Antibody Biophysics and Developability
Explore listener stats, chart rankings, contacts and more on the The Chain: Protein Engineering Podcast podcast page.